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Intestinal Transplantation in Humans Under FK 506 
S. Todo. A. Tzakis. J. Reyes, K. Abu-Elmagd, A. Casavilla. J.J. Fung, and T.E. Starzl 
A CLINICAL trial of intestinal transplantation under FK 506 was instituted in our center in May 1990. As 
of the end of June 1992, 23 patients have received either 
isolated intestinal grafts (n = 9), combined intestine and 
liver grafts (n = 12). or abdominal multivisceral grafts (n = 
2). Described herein is the clinical course of the intestinal 
transplant patients that have a minimum follow-up of 2 
months. Preliminary results of the initial cases were re-
ported previously.l.2 
METHODS 
Of the 23 patients. 12 were adult. with a mean age of 27.9 years (20 
to SO years). and 11 were children. with a mean age of 3 years (0.6 
to 10.2 years). Indications for intestinal transplantation. duration 
of total parenteral nutrition (TPN). and type of transplant are 
listed in Table 1. 
The principles and steps for intestinal harvesting and transplan-
tation have been described previously in detail.3•4 The grafts were 
obtained from ABO-matched cadaveric donon who were of 
similar or smaller size than the recipients. HLA matching was not 
considered and was univenally poor. Selective decontamination 
of the intestine was performed in all donon before procurement. 
but immunomodulation. by graft irradiation or antilymphocyte 
antibody administration. was not attempted. Grafts were pre-
served with the University of Wisconsin solution for mean dura-
tion of 7.6 houn (2.8 to 10.9 hours). Luminal flushing of the 
intestine was not performed. 
The type of intestinal grafting (ie. isolated. combined. or 
multiviscerai) was determined by the cause of intestinal failure 
and associated extraenteric orpn failure. Patieots who have 
shol't-gut syndrome or incorrectable intestinal disease but have 
normal liver function were given isolated intestinal transplants. 
Patients with short-gut syndrome and accompanyina liver failure 
were given combined intestine and liver trausplanta. Two patients 
who had thromboses of both the celiac axis and the superior 
mesenteric artery, caused by deficiencies of protein S or anti-
thrombin-III, were given multiviscerai transplants. 
Details of postoperative immunosuppression and nutritional 
management are described by Abu-Elmagd et aI. and Reyes et aI 
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T.a. 1. Clinical Featu .... of the 23 Small aow.I Tranaplant Reclplenta 
TPN PIIIenI Graft CI.rIWW 
PI. Age Sex Cauae 01 Short-Gut Syndrome Duration· GllIIIt SurvtvaI* SuMvaI* TPN Status I...ocatIan 
31.1 M Gunshot wound 6 S8 776 684 Died, sepsis 
58 71 
2 3.2 F Neaotizing enterocolitis 38 SBIL >754 >754 Free Home 
3 26.7 F SMA thrombOsis 30 SBIL >744 >744 Free Home 
4 4.3 M G8IIrOsct1isis 52 SBIL >631 >631 Free Home 
5 2.8 M Intestinal atresia 33 SBIL 385 385 Died.LPO 
6 0.8 F Intestinal atresia 6 SBIL 23 23 Died. GVHD and Sepsis 
7 1.1 F Volvulus 12 SM >372 >372 Free Home 
8 1.7 F Volvulus 18 SM >370 >370 Free SWgic:aI ward 
9 21 M Traflic accident 12 SM >381 >381 Partial SWgic:aI ward 
10 32 M CA and SMA thrombOsis 38 MY >307 >307 Free Home 
11 2.5 F Microvillus inclusion disease 29 S8 >290 >290 Free Home 
12 1.3 M Inteetinal atresia 15 S8 >235 >235 Free Home 
13 50 F Cram', disease 120 S8 >232 >232 Free Home 
14 34 F DesmoicI tumor 1 58 >195 >195 Partial Surgical ward 
15 38 M Cram', disease 120 S8 >186 >186 Free Home 
16 10.2 F Pseudo-obstruction 132 se >163 >163 Free Home 
17 22 F Cram', disease 36 S8 >157 >157 Free Home 
18 25 M Cram', disease 15 SBIL >141 >141 Free Home 
19 1.5 M Neaotizing enterocotitis 18 SBIL 70 70 Died. MOF. sepsis 
20 29 F DesrnoicI tumor 17 SM >83 >63 Free Surgical ward 
21 24 M SMV thrombosis 3 MV >80 >80 Partial Surgical ward 
22 20 F SMA Injury. MVA 24 S8 >70 >70 Free Home 
23 4.2 F Gastroschisis 50 SM >67 >87 Free Home 
K~ TPN duraIiDn In rnonIIII: ISB: small bcMeI: SBIL: small boweWIIer: MV: mullMllcenll: *SuMvIIIIn days as 01 811&'92. 
1198 Transplantation Proceedings. Vol 25. No 1 (February). 1993: pp 119&-1199 
INTESTINAL Tx IN HUMANS UNDER FK 506 
in this issue. Briefly. immunosuppression was with FK 506 
(intravenously 0.1 to 0.15 mglkgld. or orally 0.3 mglkgld). tapering 
of steroids and prostaglandin-E. (0.6 to 0.8 I-'&I'kglminl. and 
occasionallv supPlemented by Imuran. Intestinal gralt rejection 
was monitored clinically and histopathologically, using endo-
scope-guided biopsies. Treatment of graft rejection was either by 
increasing the FK 506 dose, steroid bolus. tapering of steroids. or 
OKTJ. 
RESULTS 
Of the nine isolated small bowel recipients. eight (88.8%) 
arc alive for a median duration of 6.5 months. ranging from 
2 to 23 months. One patient (case 1), who had a stormy 
immediate postoperative course and several episodes ~f 
drug-noncompliant rejection. lost his graft by chromc 
rejection at 22 months and was retransplanted (graft sur-
vival eight of ten). This patient died 71 days after retrans-
plantation by overwhelming sepsis. The median d~~tion 
of ICU stay and hospitalization of isolated graft reCIpIents 
was 6 days and 79 days, respectively. 
Nine of the 12 combined intestine and liver recipients 
(75%) are well for median follow-up of 12 months. ranging 
from 2 to 25 months. Three pediatric combined intestine 
and liver recipients died; at 23 days by sepsis and possible 
graft-versus-host disease (GVHD), at 70 days by sepsis, 
and at 385 days by postoperative lymphoproliferative 
disease. Diagnosis of GVHD was made by immunohisto-
pathologic study of a skin biopsy taken at 22 days; how-
ever, the immunohistopathology of a skin biopsy taken at 
19 days did not show any signs of GVHD. Technical 
complications, intestinal anastomotic leak, and biliary 
anastomotic leak, were major causes of sepsis in the first 
two patient deaths. The median duration of ICU stay and 
hospitalization of combined graft recipients was 14 days 
and 80 days, respectively. 
Two multivisceral transplant recipients are well for 2 
months and 10 months. respectively (100%). 
Of the 19 surviving patients, 14 are home and are 
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completely free from TPN. The remaining five patients are 
in the hospital. either for postoperative management or 
routine examination. of which two are free from TPN and 
the other three are supported by TPN partlaHy. 
DISCUSSION 
In spite of improved nutritional management of patients 
with short-gut syndrome or incorrectable intestinal dis-
ease. transplantation of the intestine has been considered 
as a theoretical modality of treatment for these patients.' 
However, the results with such attempts using conven-
tional immunosuppression have been unsatisfactory. Our 
experience has shown that small bowel transplantation in 
humans is feasible under improved immunosuppression. 
FK 506. In addition, three different types of intestinal 
grafting (isolated, combined, or multivisceral) are needed 
to treat patients depending upon the cause of intestinal 
failure and associated extraenteric organ dysfunction. 
Contrary to past experimental and clinical findings, 6. 7 the 
results associated with isolated intestinal transplantation 
are not inferior to the results obtained from transplantation 
of combined grafts. Thus. our experience suggests that 
before severe. life-threatening TPN-related complications 
occur. an isolated intestinal transplantation should be 
considered for patients who would be on TPN for life. 
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